Year 1 on GLP-1: A Realistic Recap

The first year on a GLP-1 is the part of treatment with the most data behind it. The pivotal trials — STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide — both measured their primary endpoints around the 68-72 week mark, which is close enough to one year that the published numbers are a fair benchmark for what to expect.

The reality of year one is messier than the trial data suggests. Real-world results vary more, side effects appear and resolve on individual schedules, and life circumstances during the year — stress, travel, illness, schedule changes — affect outcomes in ways trials don't capture. What follows is the honest version.

This guide walks through the typical year-one numbers, the month-by-month arc most users experience, and what the data does and does not say about where you'll likely land.

What the research shows

In STEP 1, adults on semaglutide 2.4 mg lost a mean of 14.9% of body weight at week 68, compared with 2.4% on placebo. Roughly 86% of users on active drug lost at least 5%, 69% lost at least 10%, and 50% lost at least 15%. By the end of the trial, the loss curve was nearly flat — most of the change had happened by month 9-10, with the final months consolidating the result.

SURMOUNT-1 produced higher numbers on tirzepatide. At week 72, mean weight loss was approximately 15% on the 5 mg dose, 19.5% on 10 mg, and 20.9% on 15 mg. The proportion of users reaching 20%+ loss on the 15 mg dose was about 57%, a substantially better tail than semaglutide showed. Whether tirzepatide's additional GIP agonism is the explanation or whether it's a different dose-effect relationship is still being studied, but the practical takeaway is that tirzepatide's one-year ceiling sits higher.

Real-world data is consistently lower than trial data, with one-year average losses often in the 10-14% range for semaglutide and 13-17% for tirzepatide across mixed clinical populations. The gap reflects lower titration completion, lower adherence, more variable starting BMI, and absence of the structured behavioral support that trials provided. None of this means real-world results are bad — they are just different from the headline trial numbers.

What this looks like day-to-day

The arc of year one is reasonably predictable. Months 1-3 are titration: appetite suppression appears, side effects come and go, and early weight loss is often rapid (partly fluid, partly fat). Months 4-6 are the steady-loss phase, where habits consolidate and the scale moves on a fairly linear trajectory. Months 7-9 are where the curve starts to flatten for most users — the loss slows even though the medication is unchanged. Months 10-12 are where many users reach what becomes their long-term plateau.

Side effects follow their own arc. The early nausea, fatigue, and constipation of titration usually resolve by month 3-4. New side effects that appear later in year one are uncommon and worth flagging to your prescriber. By month 12, most users describe the medication as background — the injection is a routine, not an event.

The non-scale outcomes often matter more than the weight number at the one-year mark. Blood pressure, A1C, fasting glucose, lipid panels, and waist circumference typically show meaningful improvement. For users who started with comorbidities — prediabetes, high blood pressure, sleep apnea — the year-one labs are often the part that registers most with prescribers. Your one-year review should include these metrics, not just weight.

Common questions

Keep exploring

Browse all GLP-1 guides.